Therapeutic efficacy of silibinin on human neuroblastoma cells: Akt and NF-κB expressions may play an important role in silibinin-induced response

Neurochemical Research

Volumn 37, Issue 9, 2012, Pages 2053-2063

  Yousefi, Meysam ^a,b   Ghaffari, Seyed H ^a   Soltani, Bahram M ^b   Nafissi, Shahriar ^c   Momeny, Majid ^a   Zekri, Ali ^a   Behmanesh, Mehrdad ^b   Alimoghaddam, Kamran ^a   Ghavamzadeh, Ardeshir ^a  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TARBIAT MODARES UNIVERSITY   (Iran)

^c TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Akt; MMP 2; Neuroblastoma; NF B; Silibinin

Indexed keywords

GELATINASE A; GELATINASE B; I KAPPA B KINASE; I KAPPA B KINASE 1; I KAPPA B KINASE 2; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MESSENGER RNA; PROTEIN KINASE B; SILIBININ; UNCLASSIFIED DRUG; UROKINASE RECEPTOR;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL CYCLE; CELL INVASION; CELL METABOLISM; CELL SURVIVAL; CONCENTRATION RESPONSE; CONTROLLED STUDY; ENZYME ACTIVITY; GENE EXPRESSION; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; NEUROBLASTOMA CELL; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL CYCLE; CELL LINE, TUMOR; FLOW CYTOMETRY; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LETHAL DOSE 50; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; NEUROBLASTOMA; NF-KAPPA B; ONCOGENE PROTEIN V-AKT; PROTECTIVE AGENTS; REAL-TIME POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; SILYMARIN; TETRAZOLIUM SALTS; THIAZOLES; TRANSCRIPTION, GENETIC; TUMOR STEM CELL ASSAY; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84866736330     PISSN: 03643190     EISSN: 15736903     Source Type: Journal    
DOI: 10.1007/s11064-012-0827-9     Document Type: Article

References (46)

1. Brodeur GM (2003) Neurobastoma: biological insights inro a clinical enigma. Nature 3:203-216
2. Yao R, Cooper G (1995) Requirement for phosphatidylinositol-3 kinase in the prevention of apoptosis by nerve growth factor. Science 267:2003-2006
3. Jaboin J et al (2002) Brain-derived neurotrophic factor activation of TrkB protects neuroblastoma cells from chemotherapyinduced apoptosis via phosphatidylinositol 3-kinase pathway. Cancer Res 62:6756-6763
4. Schramm A et al (2005) Biological effects of TrkA and TrkB receptor signaling in neuroblastoma. Cancer Lett 228:143-153
5. Blume-Jensen P, Hunter T (2001) Oncogenic kinase signalling. Nature 17(411):355-365
6. Vivanco I, Sawyers C (2002) The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat Rev Cancer 2:489-501
7. Cully M et al (2006) Beyond PTEN mutations: the PI3 K pathway as an integrator of multiple inputs during tumorigenesis. Nat Rev Cancer 6:184-192
8. Chakravarti A et al (2004) The prognostic significance of phosphatidylinositol 3-kinase pathway activation in human gliomas. J Clin Oncol 22:1926-1933
9. Choe G et al (2003) Analysis of the phosphatidylinositol 3-kinase signaling pathway in glioblastoma patients in vivo. Cancer Res 63:2742-2746
10. Opel D et al (2007) Activation of Akt predicts poor outcome in neuroblastoma. Cancer Res 67(2):735-745
11. Fulda S (2009) The PI3 K/Akt/mTOR pathway as therapeutic target in neuroblastoma. Curr Cancer Drug Targets 9(6):729-737
12. Engelmann J (2009) Targeting PI3 K signaling in cancer: opportunities, challenges and limitations. Nat Rev Cancer 9:550-569
13. Kane LP et al (1999) Induction of NF-kB by the Akt/PKB kinase. Curr Biol 9:601-604
14. Baud V, Karin M (2009) Is NF-kB a good target for cancer therapy? Hopes and pitfalls. Nat Rev Drug Discov 8:33-40
15. Bian X et al (2002) Constitutively active NFjB is required for the survival of S-type neuroblastoma. JBiol Chem 277(44):42144-42150
16. Smith D et al (2008) NF-kB controls growth of glioblastomas/ astrocytomas. Mol Cell Biochem 307:141-147
17. Nagai S et al (2002) Aberrant nuclear factor-kappaB activity and its participation in the growth of human malignant astrocytoma. J Neurosurg 96:909-917
18. Ara T et al (1998) Immunohistochemical expression of MMP-2, MMP-9, and TIMP-2 in neuroblastoma: association with tumor progression and clinical outcome. J Pediatr Surg 33(8):1272-1278
19. Veas Rd, Schweigerer L, Medina M (1995) Matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-2 expression in paediatric tumour cells. Effects of tumour cell proliferation modulators on gelatinolytic activity. J Cancer Res Clin Oncol 121(5):275-278
20. Cotterill S et al (2001) Late relapse and prognosis for neuroblastoma patients surviving 5 years or more: a report from the European Neuroblastoma Study Group ''Survey''. Med Pediatr Oncol 36(1):235-238
21. Mertens A et al (2001) Late mortality experience in five-year survivors of childhood and adolescent cancer: the Childhood Cancer Survivor Study. J Clin Oncol 19(13):3163-3172
22. Jacobs BP et al (2002) Milk thistle for the treatment of liver disease. A systematic review and meta-analysis. Am J Med 113:506-515
23. Deep G, Agarwal R (2010) Antimetastatic efficacy of silibinin: molecular mechanisms and therapeutic potential against cancer. Cancer Metastasis Rev 49:447-463
24. Flaig TW, Gustafson D, Su LJ, Zirrolli JA, Crighton F, Harrison GS, Pierson AS, Agarwal R, Glodé LM (2007) A phase I and pharmacokinetic study of silybin-phytosome in prostate cancer patients. Invest New Drugs 25(2):139-146
25. Momeny M et al (2010) Silibinin inhibits invasive properties of human glioblastoma U87MG cells through suppression of cathepsin B and nuclear factor kappa B-mediated induction of matrix metalloproteinase 9. Anticancer Drugs 21(3):252-260
26. Dizaji MZ, et al (2011) Synergistic effects of arsenic trioxide and silibinin on apoptosis and invasion in human Glioblastoma U87MG cell line. Neurochem Res
27. Franken NAP et al (2006) Clonogenic assay of cells in vivo. Nat Protoc 1(5):2315-2319
28. Hawkes S, Li H, Taniguchi G (2010) Zymography and reverse zymography for detecting MMPs and TIMPs. Methods Mol Biol 622:257-269
29. Eppstein A et al (2006) Differential sensitivity of chemoresistant neuroblastoma subtypes to MAPK-targeted treatment correlates with ERK, p53 expression, and signaling response to U0126. J Pediatr Surg 41(1):252-259
30. Isaacs JS et al (1998) Differential subcellular p53 localization and function in N- and S-type neuroblastoma cell lines. Cell Growth Differ 9:545-555
31. Foley NH et al (2010) MicroRNA-184 inhibits neuroblastoma cell survival through targeting the serine/threonine kinase AKT2. Mol Cancer. doi:10.1186/1476-4598-9-83
32. Abedini MR et al (2010) Akt promotes chemoresistance in human ovarian cancer cells by modulating cisplatin-induced, p53-dependent ubiquitination of FLICE-like inhibitory protein Dysregulation of FLIP ubiquitination by Akt in chemoresistant ovarian cancer. Oncogene 29:11-25
33. Gagnon V, Mathieu I, Sexton E, Leblanc K, Asselin E (2004) AKT involvement in cisplatin chemoresistance of human uterine cancer cells. Gynecol Oncol 3:785-795
34. Knuefermann C et al (2003) HER2/PI-3 K/Akt activation leads to a multidrug resistance in human breast adenocarcinoma cells. Oncogene 22:3205-3212
35. Chen J et al (2011) Insulin caused drug resistance to oxaliplatin in colon cancer cell line HT29. J Gastrointest Oncol 2(1):27-33
36. Oki E et al (2005) Akt phosphorylation associates with LOH of PTEN and leads to chemoresistance for gastric cancer. Int J Cancer 117:376-380
37. Emran M, Rebbaa A, Mirkin B (2002) Doxorubicin resistant neuroblastoma cells secrete factors that activate AKT and attenuate cytotoxicity in drug-sensitive cells. Cancer Lett 182(1):53-59
38. Li W et al (2009) Inhibition of Akt sensitises neuroblastoma cells to gold(III) porphyrin 1a, a novel antitumour drug induced apoptosis and growth inhibition. Br J Cancer 10(2):342-349
39. Singh RP et al (2005) Silibinin strongly inhibits growth and survival of human endothelial cells via cell cycle arrest and downregulation of survivin, Akt and NF-jB: implications for angioprevention and antiangiogenic therapy. Oncogene 24:1188-1202
40. Eberle K et al (2011) Carcinoma matrix controls resistance to cisplatin through talin regulation of NF-kB. PLoS One 6(6): e21469
41. Arlt A et al (2003) Role of NF-kappaB and Akt/PI3 K in the resistance of pancreatic carcinoma cell lines against gemcitabineinduced cell death. Oncogene 22:3243-3251
42. Xue Wen et al (2011) Response and resistance to NF-jB inhibitors in mouse models of lung adenocarcinoma. Cancer Discov 1: 236-247
43. Pomerantz J, Baltimore D (2002) Two pathways to NF-kappaB. Mol Cell 10:693-695
44. Derudder E et al (2003) RelB/p50 dimers are differentially regulated by tumor necrosis factor-alpha and lymphotoxin-beta receptor activation. J Biol Chem 278:23278-23284
45. Visse R, Nagase H (2003) Matrix metalloproteinases and tissue inhibitors of metalloproteinases structure, function, and biochemistry. Circ Res 92:827-839
46. Egeblad M, Werb Z (2002) New functions for matrix metalloproteinases in cancer progression. Nat Rev Cancer 2:161-173